Outlook Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell OTLK and other ETFs, options, and stocks.

About OTLK

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. 

CEO
C. Russell Trenary
CEOC. Russell Trenary
Employees
24
Employees24
Headquarters
Iselin, New Jersey
HeadquartersIselin, New Jersey
Founded
2010
Founded2010
Employees
24
Employees24

OTLK Key Statistics

Market cap
186.16M
Market cap186.16M
Price-Earnings ratio
-2.06
Price-Earnings ratio-2.06
Dividend yield
—
Dividend yield—
Average volume
193.67K
Average volume193.67K
High today
$8.26
High today$8.26
Low today
$7.81
Low today$7.81
Open price
$8.20
Open price$8.20
Volume
452.14K
Volume452.14K
52 Week high
$40.60
52 Week high$40.60
52 Week low
$4.00
52 Week low$4.00

OTLK News

Yahoo Finance 6d
Outlook Therapeutics® to Present at the Retina World Congress 2024 - Yahoo Finance

Outlook Therapeutics, Inc. ISELIN, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to ach...

Outlook Therapeutics® to Present at the Retina World Congress 2024 - Yahoo Finance

Analyst ratings

100%

of 7 ratings
Buy
100%
Hold
0%
Sell
0%
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.